Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...

Pfizer ($PFE) has long been a staple in the portfolios of income-oriented investors, especially those drawn to its consistent ...

ETFs such as The Schwab US Dividend ETF can be useful, but a 'DIY' approach can help you outperform. Here are 3 of the best ...

Once a top-performing stock thanks to its role in developing the first Covid-19 vaccine, Pfizer has seen its share price drop by nearly half from its 2021 peak.

Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic ...

One of the cornerstones of being prepared for the next pandemic is being in the best position possible to design and deploy a ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

I was taken aback by the Sept. 13 article in The Korea Times, titled 'Korea to Begin COVID-19 Vaccination Drive on Oct. 11.' The piece featured Jee Young-mee, the commissioner of the Korea Disease ...